Albert Bourla, Chairman and CEO of Pfizer Inc. (PFE), acquired 38,000 shares of the company's stock on August 12, 2026, in a transaction valued at approximately $1.00 million. The purchase was made at an average price of $26.34 per share.
This significant buy by a top executive is often interpreted as a strong signal of confidence in Pfizer's future prospects. The transaction occurred amidst other notable insider activity at the pharmaceutical giant, including recent purchases by other senior officers earlier in August.
While insider buying can indicate a bullish sentiment, it is important to note that insider selling, such as a sale by Jennifer B. Damico in early August, can occur for a variety of reasons, including personal financial planning or portfolio diversification.